The effect of Amiloride and Spironolacton on renophysiological and cardiovascular parametres in healthy patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-003336-38-DK

Enrollment

Registered

2008-09-02

Start date

2009-02-06

Completion date

Unknown

Last updated

2012-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Trade Name: Amiloride Product Name: Amiloride Pharmaceutical Form: Tablet INN or Proposed INN: AMILORIDE CAS Number: 2609463 Concentration unit: IU/mg international unit(s)/milligram Concentration typ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy subjects, 18-65 years old, normal body mass index Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Known illnesses, substance abuse, pregnancy, a wish not to participate

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate whether higher potassium leads to lowered bloodpressure;Secondary Objective: To help hypertensive patients and/or patiens with liver failure/disease;Primary end point(s): To examine changes in function of the kidneys by measuring: GFR, u-AQP2, u-ENaCß, u-cAMP, u-PGE2, CH20, FENa, FEK, pulse wave velocity, augmentation index and central bloodpressure, hormones (PRC, AngII, Aldo, AVP, ANP, BNP og Endot), To investigate the anti-hypertensiove effect by measuring 24-hour bloodpresure	—

Measure

Time frame

Main Objective: To investigate whether higher potassium leads to lowered bloodpressure;Secondary Objective: To help hypertensive patients and/or patiens with liver failure/disease;Primary end point(s): To examine changes in function of the kidneys by measuring: GFR, u-AQP2, u-ENaCß, u-cAMP, u-PGE2, CH20, FENa, FEK, pulse wave velocity, augmentation index and central bloodpressure, hormones (PRC, AngII, Aldo, AVP, ANP, BNP og Endot), To investigate the anti-hypertensiove effect by measuring 24-hour bloodpresure

—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026